The stock price of Allogene Therapeutics Inc (NASDAQ: ALLO) has surged by 3.45% when compared to previous closing price of $1.16, but the company has seen a 6.19% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-12 that Allogene Therapeutics (ALLO) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The 36-month beta value for ALLO is at 0.34. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ALLO is 149.51M, and currently, shorts hold a 17.42% of that float. The average trading volume for ALLO on July 09, 2025 was 3.05M shares.
ALLO’s Market Performance
ALLO stock saw a decrease of 6.19% in the past week, with a monthly decline of -6.98% and a quarterly a decrease of -16.67%. The volatility ratio for the week is 7.84%, and the volatility levels for the last 30 days are 7.57% for Allogene Therapeutics Inc (ALLO). The simple moving average for the past 20 days is -5.51% for ALLO’s stock, with a -37.54% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Citizens JMP, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $5. The rating they have provided for ALLO stocks is “Mkt Outperform” according to the report published on March 14th, 2025.
Oppenheimer gave a rating of “Outperform” to ALLO, setting the target price at $11 in the report published on August 08th of the previous year.
ALLO Trading at -5.84% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.25% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from MESSEMER DEBORAH M., who sale 36,885 shares at the price of $1.42 back on Jun 10 ’25. After this action, MESSEMER DEBORAH M. now owns 107,431 shares of Allogene Therapeutics Inc, valued at $52,377 using the latest closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- 12222.09 for the present operating margin
- 1.0 for the gross margin
The net margin for Allogene Therapeutics Inc stands at 11469.23. The total capital return value is set at -0.56. Equity return is now at value -59.60, with -46.11 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -812.34.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of -13696.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
In conclusion, Allogene Therapeutics Inc (ALLO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
